BIOTRONIK Announces Start of Study to Evaluate Benefits of Unique Rate Response Algorithm for Atrial Fibrillation Patients

Published
Tuesday, December 1, 2015

Randomized, Controlled B3 Trial Will Determine if Closed Loop Stimulation Can Delay Onset of Clinically Relevant AF and Reduce Risk of Stroke

BERLIN, Germany, December 1, 2015 - BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, today announced the first patient enrollments to the B3 clinical trial.

The study will evaluate the potential clinical benefit of the uniquely physiologic rate response sensor Closed Loop Stimulation (CLS) in atrial fibrillation (AF) patients. (...)

You'll find the complete article on our website in the newsroom section. Please use the following link to open the press release: For English version, please click here.

BIOTRONIK SE & Co. KG
Woermannkehre 1
12359 Berlin, Germany
Phone: +49 (0) 30 68905-1475
Mobile: +49 (0) 151 6890 1475
Fax: +49 (0) 30 68905-96 1475
Email: sarah.wandrey@biotronik.com
http://www.biotronik.com